Abstract | BACKGROUND: METHODS: RESULTS: After 24 weeks of follow-up, the percentage of patients with normalization of alanine aminotransferase levels or hepatitis B virus (HBV) DNA levels below 20,000 copies per milliliter was significantly higher with peginterferon alfa-2a monotherapy (59 percent and 43 percent, respectively) and peginterferon alfa-2a plus lamivudine (60 percent and 44 percent) than with lamivudine monotherapy (44 percent, P=0.004 and P=0.003, respectively; and 29 percent, P=0.007 and P=0.003, respectively). Rates of sustained suppression of HBV DNA to below 400 copies per milliliter were 19 percent with peginterferon alfa-2a monotherapy, 20 percent with combination therapy, and 7 percent with lamivudine alone (P<0.001 for both comparisons with lamivudine alone). Loss of hepatitis B surface antigen occurred in 12 patients in the peginterferon groups, as compared with 0 patients in the group given lamivudine alone. Adverse events, including pyrexia, fatigue, myalgia, and headache, were less frequent with lamivudine monotherapy than with peginterferon alfa-2a monotherapy or combination therapy. CONCLUSIONS:
|
Authors | Patrick Marcellin, George K K Lau, Ferruccio Bonino, Patrizia Farci, Stephanos Hadziyannis, Rui Jin, Zhi-Meng Lu, Teerha Piratvisuth, Georgios Germanidis, Cihan Yurdaydin, Moises Diago, Selim Gurel, Ming-Yang Lai, Peter Button, Nigel Pluck, Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 351
Issue 12
Pg. 1206-17
(Sep 16 2004)
ISSN: 1533-4406 [Electronic] United States |
PMID | 15371578
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2004 Massachusetts Medical Society |
Chemical References |
- Antiviral Agents
- DNA, Viral
- Hepatitis B e Antigens
- Interferon alpha-2
- Interferon-alpha
- Recombinant Proteins
- Lamivudine
- Polyethylene Glycols
- Alanine Transaminase
- peginterferon alfa-2a
|
Topics |
- Adolescent
- Adult
- Aged
- Alanine Transaminase
(blood)
- Antiviral Agents
(adverse effects, therapeutic use)
- DNA, Viral
(blood)
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Hepatitis B e Antigens
(blood)
- Hepatitis B virus
(drug effects, genetics)
- Hepatitis B, Chronic
(blood, drug therapy, virology)
- Humans
- Interferon alpha-2
- Interferon-alpha
(adverse effects, therapeutic use)
- Lamivudine
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Polyethylene Glycols
(adverse effects, therapeutic use)
- Recombinant Proteins
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|